311 related articles for article (PubMed ID: 26325060)
1. Combining inkjet printing and amorphous nanonization to prepare personalized dosage forms of poorly-soluble drugs.
Cheow WS; Kiew TY; Hadinoto K
Eur J Pharm Biopharm; 2015 Oct; 96():314-21. PubMed ID: 26325060
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the physical stability and supersaturation generation of amorphous drug-polyelectrolyte nanoparticle complex via incorporation of crystallization inhibitor at the nanoparticle formation step: A case of HPMC versus PVP.
Dong B; Lim LM; Hadinoto K
Eur J Pharm Sci; 2019 Oct; 138():105035. PubMed ID: 31386892
[TBL] [Abstract][Full Text] [Related]
3. Cost-effective alternative to nano-encapsulation: Amorphous curcumin-chitosan nanoparticle complex exhibiting high payload and supersaturation generation.
Nguyen MH; Yu H; Kiew TY; Hadinoto K
Eur J Pharm Biopharm; 2015 Oct; 96():1-10. PubMed ID: 26170159
[TBL] [Abstract][Full Text] [Related]
4. Amorphous nanodrugs prepared by complexation with polysaccharides: carrageenan versus dextran sulfate.
Cheow WS; Kiew TY; Hadinoto K
Carbohydr Polym; 2015 Mar; 117():549-558. PubMed ID: 25498670
[TBL] [Abstract][Full Text] [Related]
5. Self-assembled amorphous drug-polyelectrolyte nanoparticle complex with enhanced dissolution rate and saturation solubility.
Cheow WS; Hadinoto K
J Colloid Interface Sci; 2012 Feb; 367(1):518-26. PubMed ID: 22051687
[TBL] [Abstract][Full Text] [Related]
6. Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine.
Dong B; Hadinoto K
Drug Dev Ind Pharm; 2017 Jun; 43(6):996-1002. PubMed ID: 28121189
[TBL] [Abstract][Full Text] [Related]
7. Proof-of-concept preparation and characterization of dual-drug amorphous nanoparticle complex as fixed-dose combination of poorly soluble drugs.
Yu H; Ming Lim L; Dong B; Hadinoto K
Drug Dev Ind Pharm; 2019 Jan; 45(1):105-116. PubMed ID: 30196726
[TBL] [Abstract][Full Text] [Related]
8. Amorphous ternary nanoparticle complex of curcumin-chitosan-hypromellose exhibiting built-in solubility enhancement and physical stability of curcumin.
Lim LM; Tran TT; Long Wong JJ; Wang D; Cheow WS; Hadinoto K
Colloids Surf B Biointerfaces; 2018 Jul; 167():483-491. PubMed ID: 29727835
[TBL] [Abstract][Full Text] [Related]
9. Carboxymethyl cellulose is a superior polyanion to dextran sulfate in stabilizing and enhancing the solubility of amorphous drug-polyelectrolyte nanoparticle complex.
Dong B; Hadinoto K
Int J Biol Macromol; 2019 Oct; 139():500-508. PubMed ID: 31386874
[TBL] [Abstract][Full Text] [Related]
10. Improvement of dissolution rate of indomethacin by inkjet printing.
Wickström H; Palo M; Rijckaert K; Kolakovic R; Nyman JO; Määttänen A; Ihalainen P; Peltonen J; Genina N; de Beer T; Löbmann K; Rades T; Sandler N
Eur J Pharm Sci; 2015 Jul; 75():91-100. PubMed ID: 25817804
[TBL] [Abstract][Full Text] [Related]
11. Inkjet printing of paracetamol and indomethacin using electromagnetic technology: Rheological compatibility and polymorphic selectivity.
Kollamaram G; Hopkins SC; Glowacki BA; Croker DM; Walker GM
Eur J Pharm Sci; 2018 Mar; 115():248-257. PubMed ID: 29366961
[TBL] [Abstract][Full Text] [Related]
12. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
Pardeike J; Strohmeier DM; Schrödl N; Voura C; Gruber M; Khinast JG; Zimmer A
Int J Pharm; 2011 Nov; 420(1):93-100. PubMed ID: 21889582
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison between millifluidic and bulk-mixing platform in the synthesis of amorphous drug-polysaccharide nanoparticle complex.
Dong B; Hadinoto K
Int J Pharm; 2017 May; 523(1):42-51. PubMed ID: 28323097
[TBL] [Abstract][Full Text] [Related]
14. Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate.
Cheow WS; Hadinoto K
Colloids Surf B Biointerfaces; 2012 Apr; 92():55-63. PubMed ID: 22154010
[TBL] [Abstract][Full Text] [Related]
15. Edible solid foams as porous substrates for inkjet-printable pharmaceuticals.
Iftimi LD; Edinger M; Bar-Shalom D; Rantanen J; Genina N
Eur J Pharm Biopharm; 2019 Mar; 136():38-47. PubMed ID: 30630061
[TBL] [Abstract][Full Text] [Related]
16. Comparative investigations on key factors and print head designs for pharmaceutical inkjet printing.
Kiefer O; Breitkreutz J
Int J Pharm; 2020 Aug; 586():119561. PubMed ID: 32585176
[TBL] [Abstract][Full Text] [Related]
17. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles.
Cheow WS; Kiew TY; Yang Y; Hadinoto K
Mol Pharm; 2014 May; 11(5):1611-20. PubMed ID: 24669821
[TBL] [Abstract][Full Text] [Related]
18. Controlling the burst release of amorphous drug-polysaccharide nanoparticle complex via crosslinking of the polysaccharide chains.
Nguyen MH; Tran TT; Hadinoto K
Eur J Pharm Biopharm; 2016 Jul; 104():156-63. PubMed ID: 27179586
[TBL] [Abstract][Full Text] [Related]
19. Influence of salt type and ionic strength on self-assembly of dextran sulfate-ciprofloxacin nanoplexes.
Kutscher M; Cheow WS; Werner V; Lorenz U; Ohlsen K; Meinel L; Hadinoto K; Germershaus O
Int J Pharm; 2015; 486(1-2):21-9. PubMed ID: 25772413
[TBL] [Abstract][Full Text] [Related]
20. Re-evaluating the presumed superiority of amorphous nanoparticles over amorphous microscale solid dispersion in solubility enhancement of poorly soluble drugs.
Lim LM; Tran TT; Cheow WS; Hadinoto K
Eur J Pharm Sci; 2017 Nov; 109():455-463. PubMed ID: 28889027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
